secwatch.observer — SEC 8-K summary
======================================

Issuer:     Incannex Healthcare Inc. (IXHL)
CIK:        0001873875
Form:       8-K
Filed at:   2025-05-15T23:59:59+00:00
Accession:  0001213900-25-043706
Event type: earnings
Sentiment:  positive
Materiality: 0.65
Item codes: 8.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Incannex Q3 FY2025 net loss $3.97M, cash $6.71M, IHL-42X Phase 2 dosing done
----------------------------------------------------------------------------

- Net loss of $3.97M for quarter ended March 31, 2025, vs $6.03M same quarter last year.
- Cash and equivalents $6.71M as of March 31, up from $2.09M at Dec 31, 2024, after $12.5M private placement.
- Completed dosing of >120 patients in Phase 2 portion of RePOSA study for IHL-42X (OSA); topline data expected July 2025.
- Reported positive PK/safety study results for IHL-42X; both active components bioavailable, comparable to reference drugs.
- Formed OSA Clinical Advisory Board; appointed Alison Wimms (ResMed) as member.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1873875/000121390025043706/0001213900-25-043706-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1873875/000121390025043706/ea0242329-8k_incannex.htm
  HTML page:      https://secwatch.observer/filing/0001213900-25-043706

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer